FOXP3 and colitis: This approach not only ameliorates clinical parameters of colitis but also results in immunoregulatory changes of both effector and regulatory CD4 T cell subsets, as reflected by lower proportions of lymphocytes producing pro-inflammatory cytokines and an increase in the proportion of IL-17A+CD39+ and FOXP3+CD39+ cells in the spleen and MLNs.